BIO boosts lobbying efforts in Q1

Closing in on a 12-year market haven for biologics, the Biotechnology Industry Organization spent $2.2 million lobbying lawmakers in the first quarter. That's up 15 percent from the $1.9 lobbying bill it faces for the same period a year ago, but you won't hear anyone at BIO complaining about what they helped achieve with their push in Washington, D.C. Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.